{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GIVE&page=5",
    "query": {
      "intervention": "GIVE",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 20584,
    "total_pages": 2059,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GIVE&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GIVE&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T08:05:45.599Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00110214",
      "title": "Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1050,
      "start_date": "2005-04",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-10-22T08:05:45.599Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Chicago, Illinois",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110214"
    },
    {
      "nct_id": "NCT00349206",
      "title": "Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Recurrent Melanoma",
        "Stage III Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2006-04",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2014-04-10",
      "last_synced_at": "2026-10-22T08:05:45.599Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00349206"
    },
    {
      "nct_id": "NCT03445104",
      "title": "Effect of Huperzine A on Cognitive Function and Perception of Effort During Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cognitive Enhancement During Exercise"
      ],
      "interventions": [
        {
          "name": "Huperzine A",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 15,
      "start_date": "2018-01-16",
      "completion_date": "2018-04-05",
      "has_results": false,
      "last_update_posted_date": "2018-05-31",
      "last_synced_at": "2026-10-22T08:05:45.599Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03445104"
    },
    {
      "nct_id": "NCT07050836",
      "title": "Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioma (Any Grade) in the Brain",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Definity contrast during ultrasound",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 2,
      "start_date": "2025-12-05",
      "completion_date": "2026-01-27",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-22T08:05:45.599Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07050836"
    },
    {
      "nct_id": "NCT00433511",
      "title": "Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4994,
      "start_date": "2007-11-02",
      "completion_date": "2027-02-20",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-22T08:05:45.599Z",
      "location_count": 840,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00433511"
    },
    {
      "nct_id": "NCT05503771",
      "title": "Improving Pediatrician Counseling About Infant Safe Sleep Using the Electronic Medical Record",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sudden Infant Death",
        "Sudden Unexplained Infant Death"
      ],
      "interventions": [
        {
          "name": "ISA-MI",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Days",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "3 Days to 75 Years"
      },
      "enrollment_count": 350,
      "start_date": "2022-09-30",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-22T08:05:45.599Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05503771"
    },
    {
      "nct_id": "NCT06246409",
      "title": "Modernizing Instructions to Improve Treatment Participation of Subjects During Their First Radiotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Modernized patient instructions",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Existing patient instructions",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 650,
      "start_date": "2024-12-24",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-10-22T08:05:45.599Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06246409"
    },
    {
      "nct_id": "NCT05024916",
      "title": "Blueberry Intervention Study for Brain Aging",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain Aging"
      ],
      "interventions": [
        {
          "name": "Intervention",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "65 Years to 89 Years"
      },
      "enrollment_count": 63,
      "start_date": "2022-06-01",
      "completion_date": "2024-10-03",
      "has_results": false,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-10-22T08:05:45.599Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05024916"
    },
    {
      "nct_id": "NCT01517984",
      "title": "Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "Tacrolimus (CNI) Withdrawal",
          "type": "DRUG"
        },
        {
          "name": "Standard Immunosuppressive Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2010-11",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-22T08:05:45.599Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01517984"
    },
    {
      "nct_id": "NCT03796884",
      "title": "Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Adenoma",
        "Stage 0 Colorectal Cancer AJCC v8",
        "Stage I Colorectal Cancer AJCC v8",
        "Stage II Colorectal Cancer AJCC v8",
        "Stage IIA Colorectal Cancer AJCC v8",
        "Stage IIB Colorectal Cancer AJCC v8",
        "Stage IIC Colorectal Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Linaclotide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 150,
      "start_date": "2019-10-30",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-22T08:05:45.599Z",
      "location_count": 3,
      "location_summary": "Philadelphia, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03796884"
    }
  ]
}